Wells Fargo & Company Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price boosted by Wells Fargo & Company from $170.00 to $235.00 in a research report released on Tuesday,Benzinga reports. They currently have an overweight rating on the specialty pharmaceutical company’s stock.

Several other research analysts have also issued reports on JAZZ. Bank of America raised their target price on shares of Jazz Pharmaceuticals from $230.00 to $247.00 and gave the company a “buy” rating in a research note on Tuesday. Zacks Research raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. Robert W. Baird upped their target price on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the company an “outperform” rating in a research report on Tuesday. Weiss Ratings reissued a “sell (d)” rating on shares of Jazz Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Morgan Stanley lifted their price objective on Jazz Pharmaceuticals from $185.00 to $205.00 and gave the stock an “overweight” rating in a research note on Monday. Fourteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $195.07.

Jazz Pharmaceuticals Stock Up 6.1%

NASDAQ JAZZ opened at $180.52 on Tuesday. The stock has a market capitalization of $10.97 billion, a P/E ratio of -26.82, a price-to-earnings-growth ratio of 8.49 and a beta of 0.29. Jazz Pharmaceuticals has a 52 week low of $95.49 and a 52 week high of $182.99. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. The stock has a fifty day moving average of $135.92 and a 200-day moving average of $121.19.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.87 by $2.26. The business had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.11 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $6.54 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. On average, equities research analysts forecast that Jazz Pharmaceuticals will post 16.96 EPS for the current year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the transaction, the director directly owned 429,973 shares of the company’s stock, valued at approximately $55,303,127.26. The trade was a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 11,500 shares of company stock worth $1,525,280 in the last 90 days. Insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Krensavage Asset Management LLC grew its position in shares of Jazz Pharmaceuticals by 1.8% in the 3rd quarter. Krensavage Asset Management LLC now owns 167,816 shares of the specialty pharmaceutical company’s stock valued at $22,118,000 after purchasing an additional 3,000 shares during the period. CANADA LIFE ASSURANCE Co lifted its stake in Jazz Pharmaceuticals by 0.5% in the third quarter. CANADA LIFE ASSURANCE Co now owns 35,106 shares of the specialty pharmaceutical company’s stock valued at $4,527,000 after buying an additional 181 shares in the last quarter. Woodline Partners LP boosted its holdings in shares of Jazz Pharmaceuticals by 710.7% in the third quarter. Woodline Partners LP now owns 264,968 shares of the specialty pharmaceutical company’s stock valued at $34,923,000 after buying an additional 232,284 shares during the period. Alyeska Investment Group L.P. increased its position in shares of Jazz Pharmaceuticals by 1.0% during the third quarter. Alyeska Investment Group L.P. now owns 205,954 shares of the specialty pharmaceutical company’s stock worth $27,145,000 after acquiring an additional 2,086 shares in the last quarter. Finally, Quantessence Capital LLC acquired a new stake in shares of Jazz Pharmaceuticals during the third quarter worth $212,000. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.